Don't Panic! Novartis Is Still Invested In CAR-T Despite 2Q Silence
Novartis AG's CAR-T cell therapy CTL019, set to be the first in this class to achieve a US FDA filing, might not be an immediate blockbuster owing to its tricky treatment logistics, small initial indication and a lack of physician and patient exposure, but it is still a game changer in immuno-oncology, says Dr. Oz Azam, Novartis's head of cell therapies.
You may also be interested in...
With all eyes on the race to get the autologous cell immunotherapies to market, Kite announces it could soon see late-stage data on its lead candidate.
The FDA lifted a clinical hold on the Phase II ROCKET clinical trial for Juno's lead CAR-T therapy candidate JCAR015 less than a week after it was instituted, allowing the company to proceed without using fludarabine in a pre-conditioning chemotherapy regimen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.